EP2195019A4 - METHOD FOR TRIGGERING AN IMMUNE RESPONSE AGAINST THE PANDEMIC INFLUENZA VIRUS - Google Patents

METHOD FOR TRIGGERING AN IMMUNE RESPONSE AGAINST THE PANDEMIC INFLUENZA VIRUS

Info

Publication number
EP2195019A4
EP2195019A4 EP08800134A EP08800134A EP2195019A4 EP 2195019 A4 EP2195019 A4 EP 2195019A4 EP 08800134 A EP08800134 A EP 08800134A EP 08800134 A EP08800134 A EP 08800134A EP 2195019 A4 EP2195019 A4 EP 2195019A4
Authority
EP
European Patent Office
Prior art keywords
eliciting
immune response
influenza virus
response against
pandemic influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08800134A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2195019A1 (en
Inventor
Martin Pearse
Steve Rockman
David Ryan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Ltd
Original Assignee
CSL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Ltd filed Critical CSL Ltd
Publication of EP2195019A1 publication Critical patent/EP2195019A1/en
Publication of EP2195019A4 publication Critical patent/EP2195019A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP08800134A 2007-10-12 2008-10-09 METHOD FOR TRIGGERING AN IMMUNE RESPONSE AGAINST THE PANDEMIC INFLUENZA VIRUS Withdrawn EP2195019A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97957207P 2007-10-12 2007-10-12
PCT/AU2008/001500 WO2009046497A1 (en) 2007-10-12 2008-10-09 Method of eliciting an immune response against pandemic influenza virus

Publications (2)

Publication Number Publication Date
EP2195019A1 EP2195019A1 (en) 2010-06-16
EP2195019A4 true EP2195019A4 (en) 2012-02-15

Family

ID=40548886

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08800134A Withdrawn EP2195019A4 (en) 2007-10-12 2008-10-09 METHOD FOR TRIGGERING AN IMMUNE RESPONSE AGAINST THE PANDEMIC INFLUENZA VIRUS

Country Status (10)

Country Link
US (1) US8999353B2 (enExample)
EP (1) EP2195019A4 (enExample)
JP (1) JP2011500514A (enExample)
KR (1) KR20100082825A (enExample)
CN (1) CN101820904A (enExample)
AU (1) AU2008310312B2 (enExample)
CA (1) CA2700937C (enExample)
NZ (1) NZ583377A (enExample)
SG (1) SG185294A1 (enExample)
WO (1) WO2009046497A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2805741C (en) 2010-07-23 2019-08-13 Karin Bengtsson Loevgren Composition including an iscom matrix and ectodomains
US9524531B2 (en) * 2011-05-09 2016-12-20 Microsoft Technology Licensing, Llc Extensibility features for electronic communications
DK2750683T4 (da) * 2011-10-03 2021-04-12 Croda Int Plc Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser
CN120227451A (zh) * 2018-03-19 2025-07-01 诺瓦瓦克斯股份有限公司 多价流感纳米颗粒疫苗

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100110A1 (en) * 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Novel composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2323733A1 (en) 1998-04-13 1999-10-21 Michael B. Brenner Vaccine compositions comprising cd-1 antigens and t-cell stimulating compound and methods of use thereof
DE60044236D1 (de) * 1999-02-17 2010-06-02 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
DE60025019T2 (de) * 1999-10-29 2006-08-24 Nektar Therapeutics, San Carlos Trockenpulverzusammensetzungen mit verbesserter dispersivität
DE60039715D1 (de) * 1999-11-19 2008-09-11 Csl Ltd Hcv-impfstoff zusammensetzungen
WO2001075096A1 (en) 2000-04-04 2001-10-11 Antigenics Inc. Isolated and purified nonpeptide antigens from mycobacterium tuberculosis
MXPA02012501A (es) 2000-06-16 2003-06-06 Sembiosys Genetics Inc El uso de cuerpos grasos vegetales en sistemas de administracion de vacunas.
GB0021757D0 (en) 2000-09-04 2000-10-18 Colaco Camilo Vaccine against microbial pathogens
US20060210555A1 (en) * 2001-12-21 2006-09-21 Antigenics, Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
US20030190333A1 (en) * 2002-02-04 2003-10-09 Corixa Corporation Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
GB0401239D0 (en) 2004-01-21 2004-02-25 Molecularnature Ltd Adjuvant compositions
JP2007536273A (ja) 2004-05-07 2007-12-13 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 肺マラリアワクチン
JP2008506789A (ja) * 2004-07-18 2008-03-06 シーエスエル、リミテッド インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
US20070190072A1 (en) * 2004-09-30 2007-08-16 Csl Limited Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus adjuvant
CN101522213A (zh) * 2006-09-01 2009-09-02 Csl有限公司 引起或诱导免疫应答的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100110A1 (en) * 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Novel composition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MATTHEW R. SANDBULTE ET AL: "Cross-Reactive Neuraminidase Antibodies Afford Partial Protection against H5N1 in Mice and Are Present in Unexposed Humans", PLOS MEDICINE, vol. 4, no. 2, 1 January 2007 (2007-01-01), pages E59, XP055015444, ISSN: 1549-1277, DOI: 10.1371/journal.pmed.0040059 *
PEARSE M J ET AL: "ISCOMATRIX<TM> adjuvant: a potent inducer of humoral and cellular immune responses", VACCINE, ELSEVIER LTD, GB, vol. 22, no. 19, 23 June 2004 (2004-06-23), pages 2391 - 2395, XP004515455, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2003.12.031 *
SURYAPRAKASH SAMBHARA ET AL: "Heterotypic Protection against Influenza by Immunostimulating Complexes Is Associated with the Induction of Cross-Reactive Cytotoxic T Lymphocytes", JOURNAL OF INFECTIOUS DISEASES. JID, vol. 177, no. 5, 1 May 1998 (1998-05-01), CHICAGO, IL., pages 1266 - 1274, XP055303598, ISSN: 0022-1899, DOI: 10.1086/515285 *

Also Published As

Publication number Publication date
CN101820904A (zh) 2010-09-01
CA2700937C (en) 2017-05-09
AU2008310312B2 (en) 2013-12-19
US20100291146A1 (en) 2010-11-18
NZ583377A (en) 2013-11-29
EP2195019A1 (en) 2010-06-16
US8999353B2 (en) 2015-04-07
AU2008310312A1 (en) 2009-04-16
SG185294A1 (en) 2012-11-29
WO2009046497A1 (en) 2009-04-16
CA2700937A1 (en) 2009-04-16
KR20100082825A (ko) 2010-07-20
JP2011500514A (ja) 2011-01-06

Similar Documents

Publication Publication Date Title
IL262123A (en) Influenza virus vaccines and uses thereof
EP2552479A4 (en) INFLUENZA VIRUS VACCINES AND USES THEREOF
ZA201404797B (en) Influenza virus vaccines and uses thereof
IL186611A0 (en) Vaccine against pandemic strains of influenza viruses
IL210215A0 (en) Influenza virus-like particles (vlps) comprising hemagglutinin
PT2121011E (pt) Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
IL233175A0 (en) activation of an immune response
ZA201200481B (en) Chimeric influenza virus-like particles comprising hemagglutinin
SI2185191T1 (sl) Cepiva proti influenci z majhnimi dodatki
IL206156A0 (en) Antibodies against influenza virus and methods of use thereof
EP2118323A4 (en) DETECTION OF INFLUENZA VIRUS
AP2008004625A0 (en) Avian influenza viruses, vaccines, compositions, formulations, and methods
EP2010210A4 (en) VACCINE AGAINST BIRD FLUID AND METHOD OF APPLICATION THEREFOR
PL2851428T3 (pl) Szczepionki i diagnostyka świńskiego wirusa Torque teno
IL213189A0 (en) Recombinant avian influenza vaccine and uses thereof
PL2358386T3 (pl) Zoptymalizowane szczepionki na grypę
ZA200905952B (en) Lyophilized preparation comprising influenza vaccine,and method for preparation thereof
ZA200809056B (en) Influenza virus vaccine
GB0918679D0 (en) Influenza vaccine
ZA201100962B (en) Influenza vaccines
EP2368899B8 (en) Avian influenza vaccine
HK1144904A (en) Method of eliciting an immune response against pandemic influenza virus
EP2240199A4 (en) INFLUENZA B VACCINES
ZA200809709B (en) Detection method for influenza viruses
HK1172647A (en) Method for the preparation of an influenza virus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100329

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1144904

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20120113

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/39 20060101ALI20120109BHEP

Ipc: A61K 39/145 20060101AFI20120109BHEP

Ipc: A61P 31/16 20060101ALI20120109BHEP

17Q First examination report despatched

Effective date: 20140526

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20170227

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1144904

Country of ref document: HK